MX367154B - Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico. - Google Patents

Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.

Info

Publication number
MX367154B
MX367154B MX2014001537A MX2014001537A MX367154B MX 367154 B MX367154 B MX 367154B MX 2014001537 A MX2014001537 A MX 2014001537A MX 2014001537 A MX2014001537 A MX 2014001537A MX 367154 B MX367154 B MX 367154B
Authority
MX
Mexico
Prior art keywords
cyclopropanecarboxamido
difluorobenzo
dioxol
methylpyridin
benzoic acid
Prior art date
Application number
MX2014001537A
Other languages
English (en)
Inventor
Keshavarzshokri Ali
Zhang Beili
Krawiec Mariusz
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367154(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX367154B publication Critical patent/MX367154B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se relaciona con una forma de estado sólido sustancialmente libre y cristalina del ácido 3-(6-(1-(2, 2-difluorobenzo[D] [1,3] dioxol-5-il) ciclopropancarboxamido)-3-me tilpiridin-2-il)benzoico (Forma I) de la siguiente fórmula: (I), sus composiciones farmacéuticas y métodos para el tratamiento con las mismas. (ver Fórmula).
MX2014001537A 2007-12-07 2008-12-04 Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico. MX367154B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1216207P 2007-12-07 2007-12-07
PCT/US2008/085456 WO2009073757A1 (en) 2007-12-07 2008-12-04 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

Publications (1)

Publication Number Publication Date
MX367154B true MX367154B (es) 2019-08-07

Family

ID=40344271

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010006179A MX2010006179A (es) 2007-12-07 2008-12-04 Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
MX2014001537A MX367154B (es) 2007-12-07 2008-12-04 Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010006179A MX2010006179A (es) 2007-12-07 2008-12-04 Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.

Country Status (28)

Country Link
US (8) US8507534B2 (es)
EP (3) EP2225230B1 (es)
JP (6) JP2011506330A (es)
KR (3) KR20100101130A (es)
CN (2) CN103626744B (es)
AU (1) AU2008333845C1 (es)
BR (1) BRPI0821039B8 (es)
CA (2) CA2706920C (es)
CL (1) CL2010000607A1 (es)
CY (3) CY1118630T1 (es)
DK (2) DK2225230T3 (es)
EA (1) EA201070698A1 (es)
ES (3) ES2611077T3 (es)
HR (2) HRP20170241T2 (es)
HU (3) HUE031913T2 (es)
IL (2) IL206203A (es)
LT (3) LT3170818T (es)
MX (2) MX2010006179A (es)
NO (2) NO2017009I2 (es)
NZ (4) NZ585880A (es)
PL (2) PL2225230T3 (es)
PT (2) PT3170818T (es)
RS (2) RS60229B1 (es)
SG (1) SG186638A1 (es)
SI (2) SI3170818T1 (es)
UA (1) UA102534C2 (es)
WO (1) WO2009073757A1 (es)
ZA (1) ZA201003623B (es)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060088537A (ko) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송체의 조절자
CN1925854A (zh) * 2003-11-14 2007-03-07 沃泰克斯药物股份有限公司 可用作atp－结合弹夹转运蛋白调控剂的噻唑和噁唑
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
KR20080053297A (ko) 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
KR20150041174A (ko) * 2005-11-08 2015-04-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US7691902B2 (en) * 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
NZ611485A (en) 2006-04-07 2014-09-26 Vertex Pharma Modulators of atp-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8193194B2 (en) * 2007-05-25 2012-06-05 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
HUE028426T2 (en) 2007-08-24 2016-12-28 Vertex Pharma Isothiazolopyridinones for (inter alia) treating cystic fibrosis
WO2009064959A1 (en) * 2007-11-16 2009-05-22 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ585880A (en) 2007-12-07 2012-08-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
BRPI0820681A2 (pt) * 2007-12-07 2019-09-24 Vertex Pharma formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
US8227615B2 (en) 2008-03-31 2012-07-24 Vertex Pharmaceutical Incorporated Pyridyl derivatives as CFTR modulators
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8716338B2 (en) * 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SI2349263T1 (sl) 2008-10-23 2014-09-30 Vertex Pharmaceuticals Incorporated Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti
MX361711B (es) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Star Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
CA2777245A1 (en) * 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
NZ700556A (en) * 2010-03-25 2016-04-29 Vertex Pharma Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK2555754T3 (en) 2010-04-07 2016-04-18 Vertex Pharma Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CA2796646A1 (en) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2560650A1 (en) * 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
SG10201913594UA (en) 2010-04-22 2020-02-27 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US9856240B2 (en) * 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN104039775B (zh) 2011-11-08 2017-03-01 弗特克斯药品有限公司 Atp‑结合盒转运蛋白的调节剂
CN108066306B (zh) * 2012-01-25 2021-09-07 沃泰克斯药物股份有限公司 药物制剂及其制备方法
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
HUE070382T2 (hu) 2012-11-02 2025-06-28 Vertex Pharma Gyógyászati készítmények CFTR közvetített betegségek kezelésére
KR101943490B1 (ko) 2013-03-13 2019-04-17 플랫틀리 디스커버리 랩, 엘엘씨 피리다지논 화합물 및 낭성 섬유증을 치료하는 방법
MX385244B (es) 2013-11-12 2025-03-14 Vertex Pharma Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
MX387720B (es) 2014-04-15 2025-03-12 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107110831B (zh) 2014-11-18 2020-02-21 弗特克斯药品有限公司 进行高通量试验高效液相色谱的方法
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
WO2017017696A1 (en) * 2015-07-27 2017-02-02 Mylan Laboratories Limited Process for the preparation of lumacaftor
CN106432209A (zh) * 2015-08-11 2017-02-22 苏州晶云药物科技有限公司 Lumacaftor的新晶型及其制备方法
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
WO2017056109A2 (en) 2015-09-29 2017-04-06 Mylan Laboratories Limited Novel forms of lumacaftor and processes for the preparation thereof
WO2017056031A1 (en) * 2015-10-01 2017-04-06 Glenmark Pharmaceuticals Limited Process for preparation of lumacaftor
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
WO2017118915A1 (en) * 2016-01-04 2017-07-13 Dr. Reddy's Laboratories Limited Amorphous and crystalline solid forms of lumacaftor or its complex and preparative processes thereof
WO2017137900A1 (en) 2016-02-10 2017-08-17 Lupin Limited Amorphous lumacaftor and its solid dispersion
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
HUP1600271A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10376501B2 (en) 2016-04-25 2019-08-13 Druggability Technologies Ip Holdco Limited Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PT3519401T (pt) 2016-09-30 2021-12-27 Vertex Pharma Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
US10432856B2 (en) * 2016-10-27 2019-10-01 Mediatek Inc. Method and apparatus of video compression for pre-stitched panoramic contents
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
EP3565814B1 (en) 2017-01-09 2024-07-10 Laurus Labs Limited Process and crystalline forms of lumacaftor
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CA3020592A1 (en) * 2017-10-17 2019-04-17 Apotex Inc. Novel crystalline form of lumacaftor
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
KR102720000B1 (ko) 2017-12-01 2024-10-21 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막관통 조절 인자의 제조 방법
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019136314A1 (en) 2018-01-05 2019-07-11 The Curators Of The University Of Missouri Compounds and methods for treatment of cystic fibrosis
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
IL294042B2 (en) 2018-02-15 2026-01-01 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance, their pharmaceutical compounds, their use in the treatment of cystic fibrosis, and a process for their preparation.
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
MX2022001827A (es) 2019-08-14 2022-06-09 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2021095015A1 (en) * 2019-11-15 2021-05-20 Laurus Labs Limited Solid forms of tezacaftor, processes for their preparation and pharmaceutical compositions thereof
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2023537944A (ja) 2020-08-13 2023-09-06 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレーターの結晶形態
MX2023001993A (es) 2020-08-20 2023-02-27 Univ Leland Stanford Junior Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.
WO2022076620A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
GEP20257824B (en) 2020-10-07 2025-11-10 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
IL301756A (en) 2020-10-07 2023-05-01 Vertex Pharma Cystic fibrosis transmembrane regulator conductance modulators
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TW202233635A (zh) 2020-10-07 2022-09-01 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
AU2023218262A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PE20250606A1 (es) 2022-04-06 2025-02-26 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
JP2025517323A (ja) 2022-05-16 2025-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレーターとしての大環状化合物の固体形態及びその調製
JP2025517322A (ja) 2022-05-16 2025-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
EP4321162A1 (en) 2022-08-08 2024-02-14 Consejo Superior de Investigaciones Científicas (CSIC) Antiviral agents for the treatment of infections by coronaviruses
CN119894906A (zh) 2022-09-15 2025-04-25 爱杜西亚药品有限公司 大环cftr调节剂
US20250268979A1 (en) 2022-09-15 2025-08-28 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758475A (en) 1971-07-20 1973-09-11 Sandoz Ag Pyrido(2,3-d)pyrimidin 2 ones
IT1226048B (it) 1981-12-14 1990-12-10 Medea Res Srl Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
EP0081756B1 (en) 1981-12-14 1985-05-15 MEDEA RESEARCH S.r.l. New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
EP0278374A3 (de) 1987-02-06 1989-03-01 Pharmatest Apparatebau Gmbh Vorrichtung zur Bestimmung der Wirkstoff-Freigabe von pharmazeutischen Produkten
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5981714A (en) 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja) 1990-11-27 2001-05-21 武田薬品工業株式会社 ピリドピリダジン誘導体およびその用途
AU3136293A (en) 1991-11-15 1993-06-15 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2107196A1 (en) 1992-09-29 1994-03-30 Mitsubishi Chemical Corporation Carboxamide derivatives
US6060024A (en) 1993-07-14 2000-05-09 Zymark Corporation Automatic dissolution testing system
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
CA2173468A1 (en) 1993-10-21 1995-04-27 Donald W. Hansen, Jr. Amidino derivatives useful as nitric oxide synthase inhibitors
DE4405712A1 (de) 1994-02-23 1995-08-24 Basf Ag Substituierte Naphthyridine und deren Verwendung
CA2146701A1 (en) 1994-04-11 1995-10-12 Takashi Fujita Heterocyclic compounds having anti-diabetic activity, their preparation and their use
WO1996010027A1 (en) 1994-09-27 1996-04-04 Janssen Pharmaceutica N.V. N-substituted piperidinyl bicyclic benzoate derivatives
ATE216080T1 (de) 1994-10-28 2002-04-15 Sophion Bioscience As Patch-clamp-vorrichtung und -technik mit hohem durchfluss und niedrigen flüssigkeitsvolumenanforderungen
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US6849733B1 (en) 1996-08-23 2005-02-01 Agouron Pharmaceuticals, Inc. Neuropeptide-Y ligands
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
IL135177A0 (en) 1997-10-02 2001-05-20 Sankyo Co Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
EP1054996B1 (en) 1998-02-17 2004-01-28 G.D. SEARLE & CO. Process for the enzymatic resolution of lactams
CA2334298C (en) 1998-06-08 2008-01-08 Schering Corporation Neuropeptide y5 receptor antagonists
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
CA2347770A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HRP20010604A2 (en) 1999-02-24 2002-08-31 Hoffmann La Roche 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
KR100514236B1 (ko) 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
DK1035115T3 (da) 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
JP3472180B2 (ja) 1999-03-08 2003-12-02 日本電信電話株式会社 ３次元周期構造体及び２次元周期構造体並びにそれらの作製方法
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CN1356988A (zh) 1999-06-18 2002-07-03 拜尔公司 苯氧基氟代嘧啶类化合物
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
AU2010601A (en) 1999-12-16 2001-07-03 Novartis Ag Organic compounds
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
AU2001233069A1 (en) 2000-01-28 2001-08-07 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001056989A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
AU2001249417A1 (en) 2000-04-26 2001-11-07 Gliatech, Inc. Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2001083517A1 (en) 2000-05-03 2001-11-08 Tularik Inc. Stat4 and stat6 binding dipeptide derivatives
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AP2003002762A0 (en) 2000-09-15 2003-03-31 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2002211379A1 (en) 2000-10-04 2002-04-15 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
DE60104014T2 (de) 2000-10-20 2005-08-11 Merck Patent Gmbh Chirale binaphtol-verbindungen
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
EP1339402B1 (en) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US6962674B2 (en) 2001-02-28 2005-11-08 Varian, Inc. Dissolution test apparatus
EP1383799A4 (en) 2001-04-10 2008-08-06 Transtech Pharma Inc PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS
CN100398106C (zh) 2001-04-23 2008-07-02 弗·哈夫曼-拉罗切有限公司 Nk-1受体拮抗剂对抗良性前列腺增生的用途
RU2003134010A (ru) 2001-05-22 2005-05-20 Ньюроджин Корпорейшн (US) 5-замещенные-2-арилпиридины в качестве модуляторов crf1
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
JP2003221386A (ja) 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
BR0215212A (pt) 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
EP1546089A2 (en) 2002-08-09 2005-06-29 TransTech Pharma Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
PL376147A1 (en) 2002-09-30 2005-12-27 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP3546208B2 (ja) 2002-10-02 2004-07-21 明治製菓株式会社 経口吸収性が改善された抗菌性医薬組成物
EP1554271A1 (en) 2002-10-15 2005-07-20 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
JP2006507301A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のピペリジニルシクロペンチルアリールベンジルアミドモジュレーター
AU2003287449A1 (en) 2002-10-31 2004-05-25 Nanostream, Inc. Parallel detection chromatography systems
AU2003288182A1 (en) 2002-11-26 2004-06-18 Universiteit Gent Process and apparatus for continuous wet granulation of power material
WO2004054505A2 (en) 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
EP2562158A1 (en) 2003-02-10 2013-02-27 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20050113423A1 (en) 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
HUE055434T2 (hu) 2003-04-11 2021-11-29 Ptc Therapeutics Inc 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére
KR20060006953A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
ES2386721T3 (es) 2003-06-27 2012-08-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compuestos de piridinio anfifilos , método de fabricación y utilización de los mismos
JP2005053902A (ja) 2003-07-18 2005-03-03 Nippon Nohyaku Co Ltd フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
ZA200601978B (en) 2003-09-05 2007-05-30 Neurogen Corp Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
KR20060088537A (ko) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송체의 조절자
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CN1886393A (zh) 2003-10-08 2006-12-27 沃泰克斯药物股份有限公司 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
FR2861304B1 (fr) 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN1925854A (zh) 2003-11-14 2007-03-07 沃泰克斯药物股份有限公司 可用作atp－结合弹夹转运蛋白调控剂的噻唑和噁唑
EP1687001A2 (en) 2003-11-19 2006-08-09 Glaxo Group Limited Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
JP3746062B2 (ja) 2003-12-05 2006-02-15 第一製薬株式会社 固形製剤およびその製造方法
ES2238001B1 (es) * 2004-01-21 2006-11-01 Vita Cientifica, S.L. Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
MXPA06008606A (es) 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7522995B2 (en) 2004-02-05 2009-04-21 Nortrup Edward H Method and system for providing travel time information
CN100567270C (zh) 2004-02-19 2009-12-09 万有制药株式会社 磺酰胺衍生物
KR20130041346A (ko) 2004-03-25 2013-04-24 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
EA011074B1 (ru) 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
WO2005115399A2 (en) 2004-04-16 2005-12-08 Neurogen Corporation Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
JP2007533741A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤
CA2568499A1 (en) 2004-06-01 2005-12-15 Tm Bioscience Corporation Method of detecting cystic fibrosis associated mutations
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
TWI356036B (en) 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
JP2008504097A (ja) 2004-07-01 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ナノ粒子を含有する医薬組成物の調製
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
MX2007001215A (es) 2004-08-06 2007-04-17 Otsuka Pharma Co Ltd Compuestos aromaticos.
AU2005289426A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
CN101072758B (zh) 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 喹唑啉衍生物
EP1812071A2 (en) 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
JP5036126B2 (ja) 2004-10-19 2012-09-26 日医工株式会社 エバスチン経口投与用製剤
WO2006051394A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
WO2006063999A1 (en) 2004-12-15 2006-06-22 Dompe' Pha.R.Ma.S.P.A. 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
JP4790260B2 (ja) 2004-12-22 2011-10-12 出光興産株式会社 アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
JP5028275B2 (ja) 2005-01-25 2012-09-19 バイエル・クロップサイエンス・アーゲー 亜リン酸、ホセチル−Ａｌ又は両者を同時に分析する方法
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
JPWO2006082952A1 (ja) 2005-02-01 2008-06-26 武田薬品工業株式会社 アミド化合物
JP5385605B2 (ja) 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
WO2006101740A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
EP1874317A4 (en) 2005-04-19 2011-10-26 Bayer Healthcare Llc PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES IN THE TREATMENT OF OBESITY
CN101160126A (zh) * 2005-04-20 2008-04-09 默克公司 血管紧张肽ⅱ受体拮抗剂
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
AU2006251624A1 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
EP1919875A2 (en) 2005-06-21 2008-05-14 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
ES2367844T3 (es) 2005-08-11 2011-11-10 Vertex Pharmaceuticals, Inc. Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
KR20080053297A (ko) 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
DK1928886T3 (da) 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
MY143784A (en) 2005-09-23 2011-07-15 Hoffmann La Roche Novel dosage formulation
CA2624683A1 (en) 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
BRPI0618417A2 (pt) 2005-10-19 2012-07-31 Gruenenthal Chemie novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
KR20150041174A (ko) 2005-11-08 2015-04-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
WO2007054480A1 (en) 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
GB0606891D0 (en) 2006-04-05 2006-05-17 Council Cent Lab Res Councils Raman Analysis Of Pharmaceutical Tablets
CN101326182B (zh) 2005-12-05 2011-09-28 史密丝克莱恩比彻姆公司 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂
EP1979367A2 (en) 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
WO2007075946A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7691902B2 (en) 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
WO2007079257A2 (en) 2005-12-30 2007-07-12 Caliper Life Sciences, Inc. Integrated dissolution processing and sample transfer system
NZ611485A (en) 2006-04-07 2014-09-26 Vertex Pharma Modulators of atp-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7553855B2 (en) 2006-05-12 2009-06-30 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20090252790A1 (en) 2006-05-13 2009-10-08 Novo Nordisk A/S Tablet formulation
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008127399A2 (en) 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5318400B2 (ja) 2006-11-20 2013-10-16 第一三共株式会社 レボフロキサシン含有錠剤
CA2670105A1 (en) 2006-11-27 2008-06-05 Novartis Ag Substituted dihydroimidazoles and their use in the treatment of tumors
JP5023716B2 (ja) 2007-01-25 2012-09-12 カシオ計算機株式会社 蒸発型ゲッター材、ゲッターポンプ、減圧構造、反応装置、発電装置及び電子機器
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
NZ581324A (en) 2007-05-02 2012-05-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
HUE028426T2 (en) 2007-08-24 2016-12-28 Vertex Pharma Isothiazolopyridinones for (inter alia) treating cystic fibrosis
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
CA2699292A1 (en) 2007-09-14 2009-03-26 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2201010B1 (en) 2007-09-14 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8118283B2 (en) 2007-09-21 2012-02-21 Lanny Vlasak Apparatus for aerating an aqueous solution
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
WO2009064959A1 (en) 2007-11-16 2009-05-22 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
DE102007058718A1 (de) 2007-12-06 2009-06-10 Erweka Gmbh Vorrichtung und Verfahren zur automatischen Freisetzung und Messung von Wirkstoffen aus einer Arzneizubereitung
NZ585880A (en) 2007-12-07 2012-08-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
BRPI0820681A2 (pt) 2007-12-07 2019-09-24 Vertex Pharma formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
EP2231671B1 (en) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2249838A4 (en) 2008-02-05 2012-05-02 Harbor Biosciences Inc Pharmaceutical solid state forms
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
WO2009111228A2 (en) 2008-02-29 2009-09-11 Waters Technologies Corporation Chromatography-based monitoring and control of multiple process streams
US8227615B2 (en) 2008-03-31 2012-07-24 Vertex Pharmaceutical Incorporated Pyridyl derivatives as CFTR modulators
GB0813709D0 (en) 2008-07-26 2008-09-03 Univ Dundee Method and product
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP3345625B1 (en) 2008-08-13 2020-12-09 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8716338B2 (en) 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
NZ592687A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
SI2349263T1 (sl) 2008-10-23 2014-09-30 Vertex Pharmaceuticals Incorporated Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti
KR20110074916A (ko) 2008-10-23 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태
CA2740836C (en) 2008-10-31 2017-03-21 Biomerieux, Inc. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
PT2365972E (pt) 2008-11-06 2015-03-31 Vertex Pharma Moduladores de transportadores de cassetes de ligação à atp
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX361711B (es) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Star Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
HRP20181261T1 (hr) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Modulatori regulatora transmembranske provodljivosti cistične fibroze
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
JP2012525895A (ja) 2009-05-07 2012-10-25 ジーイーエイ・ファーマ・システムズ・リミテッド 錠剤の製造モジュール及び錠剤の連続製造方法
JP5355269B2 (ja) 2009-07-16 2013-11-27 大日本住友製薬株式会社 顕微ラマン分光法による固体材料中の分散粒子の粒径の測定法
BR112012006031A2 (pt) 2009-09-17 2019-09-24 Vertex Pharma processo para preparação de compostos azabicíclicos.
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
NZ600172A (en) 2009-10-23 2014-07-25 Vertex Pharma Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
CN102666546B (zh) 2009-10-23 2015-09-09 沃泰克斯药物股份有限公司 N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式
US8471029B2 (en) 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ700556A (en) 2010-03-25 2016-04-29 Vertex Pharma Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
DK2555754T3 (en) 2010-04-07 2016-04-18 Vertex Pharma Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
SG10201913594UA (en) 2010-04-22 2020-02-27 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
EP2560650A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CA2796646A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US20110288122A1 (en) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Pharmaceutical Compositions and Administrations Thereof
WO2011146886A1 (en) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
NZ607494A (en) 2010-08-27 2015-04-24 Vertex Pharma Pharmaceutical composition and administrations thereof
CN102058889A (zh) 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP5798400B2 (ja) 2011-07-26 2015-10-21 富士電機株式会社 医薬品製造制御装置、医薬品製造制御方法、医薬品製造制御プログラム、医薬品製造システム
CN102507770A (zh) 2011-10-25 2012-06-20 中国检验检疫科学研究院 检测化妆品中六氯酚的高效液相色谱法
CN103073508B (zh) * 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
AU2012332225A1 (en) 2011-11-02 2014-05-15 Vertex Pharmaceuticals Incorporated Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
CN104039775B (zh) 2011-11-08 2017-03-01 弗特克斯药品有限公司 Atp‑结合盒转运蛋白的调节剂
CN108066306B (zh) 2012-01-25 2021-09-07 沃泰克斯药物股份有限公司 药物制剂及其制备方法
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2013253790A (ja) 2012-06-05 2013-12-19 Chube Univ ニバレノールの分析法
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
US20140092376A1 (en) 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
HUE070382T2 (hu) 2012-11-02 2025-06-28 Vertex Pharma Gyógyászati készítmények CFTR közvetített betegségek kezelésére
WO2014089216A1 (en) 2012-12-04 2014-06-12 Tekmira Pharmaceuticals Corporation In vitro release assay for liposome encapsulated vincristine
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
CN103743826B (zh) 2013-08-28 2015-12-02 合肥久诺医药科技有限公司 一种阿齐沙坦的高效液相色谱分析方法
CN103822976B (zh) 2013-10-15 2015-05-27 辽宁省食品药品检验所 一种测定化妆品中4-甲氧基水杨酸钾的方法
MX385244B (es) 2013-11-12 2025-03-14 Vertex Pharma Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
MX387720B (es) 2014-04-15 2025-03-12 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
CN104090038B (zh) 2014-07-07 2015-09-30 黄宏南 一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法
CN104122346B (zh) 2014-07-31 2016-03-16 国家烟草质量监督检验中心 一种水基胶中尿素含量的测定方法
CN104122345B (zh) 2014-07-31 2015-08-12 国家烟草质量监督检验中心 烟用纸中1,1,1-三羟甲基丙烷的测定方法
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107110831B (zh) 2014-11-18 2020-02-21 弗特克斯药品有限公司 进行高通量试验高效液相色谱的方法
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
EP3226861A2 (en) 2014-12-05 2017-10-11 Centre National de la Recherche Scientifique (CNRS) Compounds for treating cystic fibrosis
EP3767448A3 (en) 2015-01-07 2021-04-07 Samsung Electronics Co., Ltd. Display device and operating method thereof
WO2016123028A1 (en) 2015-01-26 2016-08-04 Rigel Pharmaceuticals, Inc. Tetrazolones as carboxylic acid bioisosteres
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
CN105890945A (zh) 2016-04-01 2016-08-24 中国热带农业科学院分析测试中心 超声离心渗液进样快速测定土壤中速效钾的方法
WO2018183367A1 (en) 2017-03-28 2018-10-04 Van Goor Fredrick F Methods of treating cystic fibrosis in patients with residual function mutations

Also Published As

Publication number Publication date
HUS2000030I1 (hu) 2020-09-28
EP3170818A1 (en) 2017-05-24
ES2790830T3 (es) 2020-10-29
CL2010000607A1 (es) 2011-03-11
HRP20200664T1 (hr) 2020-07-24
IL206203A0 (en) 2010-12-30
US12065432B2 (en) 2024-08-20
US20140011846A1 (en) 2014-01-09
KR20160040745A (ko) 2016-04-14
JP2011506330A (ja) 2011-03-03
RS55559B1 (sr) 2017-05-31
SG186638A1 (en) 2013-01-30
JP2013253111A (ja) 2013-12-19
PT3170818T (pt) 2020-05-13
DK2225230T3 (en) 2017-01-23
BRPI0821039B1 (pt) 2021-05-11
RS60229B1 (sr) 2020-06-30
US20160052916A1 (en) 2016-02-25
HUE049642T2 (hu) 2020-09-28
US20090170905A1 (en) 2009-07-02
MX2010006179A (es) 2010-08-04
BRPI0821039A2 (pt) 2015-06-16
NZ702159A (en) 2016-03-31
NZ599889A (en) 2013-09-27
UA102534C2 (xx) 2013-07-25
LT2225230T (lt) 2017-01-25
ES2611077T3 (es) 2017-05-04
US10597384B2 (en) 2020-03-24
IL206203A (en) 2016-07-31
CN103626744A (zh) 2014-03-12
JP2015145426A (ja) 2015-08-13
CA2706920A1 (en) 2009-06-11
EP2225230B1 (en) 2016-11-16
NZ585880A (en) 2012-08-31
LTC3170818I2 (lt) 2023-05-25
KR20100101130A (ko) 2010-09-16
US9150552B2 (en) 2015-10-06
US8507534B2 (en) 2013-08-13
LT3170818T (lt) 2020-05-25
US9840499B2 (en) 2017-12-12
HK1146819A1 (en) 2011-07-15
IL246644A0 (en) 2016-08-31
CY2020030I1 (el) 2020-11-25
HRP20170241T2 (hr) 2023-03-17
AU2008333845A1 (en) 2009-06-11
CA2986286C (en) 2019-04-23
CY1122895T1 (el) 2020-11-25
NO2017009I1 (no) 2017-03-24
US8846718B2 (en) 2014-09-30
ZA201003623B (en) 2011-08-31
JP2014088447A (ja) 2014-05-15
US20180127398A1 (en) 2018-05-10
CY1118630T1 (el) 2017-07-12
AU2008333845B2 (en) 2013-07-18
EP3683218A1 (en) 2020-07-22
US20120277268A1 (en) 2012-11-01
CA2986286A1 (en) 2009-06-11
AU2008333845C1 (en) 2014-01-16
US8653103B2 (en) 2014-02-18
DK3170818T3 (da) 2020-04-14
US20140371275A1 (en) 2014-12-18
US20160221995A1 (en) 2016-08-04
HRP20170241T1 (hr) 2017-04-07
KR20150063170A (ko) 2015-06-08
NO2017009I2 (no) 2018-11-19
EP3683218B1 (en) 2024-09-18
PL2225230T3 (pl) 2017-08-31
HUE031913T2 (en) 2017-08-28
SI3170818T1 (sl) 2020-08-31
CA2706920C (en) 2018-02-13
EA201070698A1 (ru) 2011-02-28
CN101910156B (zh) 2013-12-04
SI2225230T1 (sl) 2017-03-31
CN103626744B (zh) 2016-05-11
PL3170818T3 (pl) 2020-09-21
CY2020030I2 (el) 2020-11-25
NO2020025I1 (no) 2020-08-12
US20200377484A1 (en) 2020-12-03
ES2993060T3 (en) 2024-12-20
PT2225230T (pt) 2016-12-07
JP6227741B2 (ja) 2017-11-08
BRPI0821039B8 (pt) 2021-05-25
US9434717B2 (en) 2016-09-06
CN101910156A (zh) 2010-12-08
LTPA2020525I1 (lt) 2020-09-10
EP3170818B1 (en) 2020-02-19
NZ614151A (en) 2015-04-24
EP2225230A1 (en) 2010-09-08
JP2017014290A (ja) 2017-01-19
WO2009073757A1 (en) 2009-06-11
JP2017149778A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2010006179A (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
MX2010006238A (es) Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
WO2011127290A3 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP4253381A3 (en) Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide
WO2010037066A3 (en) Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2007135527A3 (en) Benzimidazolyl compounds
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
TW200833675A (en) Nicotinamide derivatives
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
NO20070089L (no) DPP-IV inhibitorer
NO20085052L (no) 4-((fluorofenoksyl)fenylmetyl)piperidin metansulfonat: anvendelser, synteseprosess og farmasoytiske sammensetninger
WO2008087654A3 (en) PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2008059513A3 (en) Compounds suitable as modulators of hdl
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
GEP20094745B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same
WO2010122580A3 (en) Piperidine derivatives as inhibitors of renin
GEP20094744B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same
WO2006123229A3 (en) Novel heterocyclic derivatives
WO2007029062A3 (en) Novel pyridine derivatives
UA84306C2 (en) Endo-3-(2,2,6,6-tetramethyl-1-piperidylcarbonyl)bicyclo[2.2.1]hept-5-en-endo-2-carboxylic acid having analgetic, tranquilizing and antispasmodic action
UA99734C2 (ru) Производные азабифениламинобензойной кислоты как ингибиторы dhodh